AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more
Market Cap & Net Worth: AbL Diagnostics SA (ABLD)
AbL Diagnostics SA (PA:ABLD) has a market capitalization of $53.14 Million (€51.77 Million) as of March 18, 2026. Listed on the PA stock exchange, this France-based company holds position #37911 globally and #471 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AbL Diagnostics SA's stock price €3.22 by its total outstanding shares 16078405 (16.08 Million).
AbL Diagnostics SA Market Cap History: 2015 to 2026
AbL Diagnostics SA's market capitalization history from 2015 to 2026. Data shows growth from $38.76 Million to $53.14 Million (3.12% CAGR).
Index Memberships
AbL Diagnostics SA is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Financials
FRFIN
|
$3.33 Billion | 0.01% | #14 of 31 |
Weight: AbL Diagnostics SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AbL Diagnostics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AbL Diagnostics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.62x
AbL Diagnostics SA's market cap is 7.62 times its annual revenue
1.54x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
142.37x
AbL Diagnostics SA's market cap is 142.37 times its annual earnings
252.98x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $38.76 Million | $322.10K | -$281.00K | 120.35x | N/A |
| 2016 | $68.74 Million | $550.13K | -$499.00K | 124.95x | N/A |
| 2017 | $51.58 Million | $655.83K | -$25.10K | 78.64x | N/A |
| 2018 | $66.43 Million | $343.34K | -$455.00K | 193.48x | N/A |
| 2022 | $238.52 Million | $8.75 Million | $1.11 Million | 27.26x | 215.72x |
| 2023 | $160.09 Million | $5.61 Million | $54.36K | 28.52x | 2944.98x |
| 2024 | $40.60 Million | $5.33 Million | $285.17K | 7.62x | 142.37x |
Competitor Companies of ABLD by Market Capitalization
Companies near AbL Diagnostics SA in the global market cap rankings as of March 18, 2026.
Key companies related to AbL Diagnostics SA by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #724 globally with a market cap of $28.17 Billion USD.
- BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ:BTSGU): Ranked #989 globally with a market cap of $19.86 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2240 globally with a market cap of $6.77 Billion USD.
- HealthEquity Inc (NASDAQ:HQY): Ranked #2273 globally with a market cap of $6.65 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #724 | Veeva Systems Inc Class A | NYSE:VEEV | $28.17 Billion | $186.70 |
| #989 | BrightSpring Health Services, Inc. Tangible Equity Unit | NASDAQ:BTSGU | $19.86 Billion | $139.72 |
| #2240 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $6.77 Billion | $42.10 |
| #2273 | HealthEquity Inc | NASDAQ:HQY | $6.65 Billion | $79.40 |
AbL Diagnostics SA Historical Marketcap From 2015 to 2026
Between 2015 and today, AbL Diagnostics SA's market cap moved from $38.76 Million to $ 53.14 Million, with a yearly change of 3.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €53.14 Million | +7.33% |
| 2025 | €49.51 Million | +21.95% |
| 2024 | €40.60 Million | -74.64% |
| 2023 | €160.09 Million | -32.88% |
| 2022 | €238.52 Million | +627.14% |
| 2021 | €32.80 Million | +34.75% |
| 2020 | €24.34 Million | -62.66% |
| 2019 | €65.19 Million | -1.86% |
| 2018 | €66.43 Million | +28.80% |
| 2017 | €51.58 Million | -24.97% |
| 2016 | €68.74 Million | +77.32% |
| 2015 | €38.76 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AbL Diagnostics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.14 Million USD |
| MoneyControl | $53.14 Million USD |
| MarketWatch | $53.14 Million USD |
| marketcap.company | $53.14 Million USD |
| Reuters | $53.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.